Anti-aggregation Effects of Phenolic Compounds on α-synuclein

The aggregation and deposition of α-synuclein (αS) are major pathologic features of Parkinson’s disease, dementia with Lewy bodies, and other α-synucleinopathies. The propagation of αS pathology in the brain plays a key role in the onset and progression of clinical phenotypes. Thus, there is increas...

Full description

Bibliographic Details
Main Authors: Kenjiro Ono, Mayumi Tsuji, Tritia R. Yamasaki, Giulio M. Pasinetti
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/25/10/2444
_version_ 1797567152180428800
author Kenjiro Ono
Mayumi Tsuji
Tritia R. Yamasaki
Giulio M. Pasinetti
author_facet Kenjiro Ono
Mayumi Tsuji
Tritia R. Yamasaki
Giulio M. Pasinetti
author_sort Kenjiro Ono
collection DOAJ
description The aggregation and deposition of α-synuclein (αS) are major pathologic features of Parkinson’s disease, dementia with Lewy bodies, and other α-synucleinopathies. The propagation of αS pathology in the brain plays a key role in the onset and progression of clinical phenotypes. Thus, there is increasing interest in developing strategies that attenuate αS aggregation and propagation. Based on cumulative evidence that αS oligomers are neurotoxic and critical species in the pathogenesis of α-synucleinopathies, we and other groups reported that phenolic compounds inhibit αS aggregation including oligomerization, thereby ameliorating αS oligomer-induced cellular and synaptic toxicities. Heterogeneity in gut microbiota may influence the efficacy of dietary polyphenol metabolism. Our recent studies on the brain-penetrating polyphenolic acids 3-hydroxybenzoic acid (3-HBA), 3,4-dihydroxybenzoic acid (3,4-diHBA), and 3-hydroxyphenylacetic acid (3-HPPA), which are derived from gut microbiota-based metabolism of dietary polyphenols, demonstrated an in vitro ability to inhibit αS oligomerization and mediate aggregated αS-induced neurotoxicity. Additionally, 3-HPPA, 3,4-diHBA, 3-HBA, and 4-hydroxybenzoic acid significantly attenuated intracellular αS seeding aggregation in a cell-based system. This review focuses on recent research developments regarding neuroprotective properties, especially anti-αS aggregation effects, of phenolic compounds and their metabolites by the gut microbiome, including our findings in the pathogenesis of α-synucleinopathies.
first_indexed 2024-03-10T19:37:36Z
format Article
id doaj.art-557de1d995d14776a56c908c2aa62ef7
institution Directory Open Access Journal
issn 1420-3049
language English
last_indexed 2024-03-10T19:37:36Z
publishDate 2020-05-01
publisher MDPI AG
record_format Article
series Molecules
spelling doaj.art-557de1d995d14776a56c908c2aa62ef72023-11-20T01:32:40ZengMDPI AGMolecules1420-30492020-05-012510244410.3390/molecules25102444Anti-aggregation Effects of Phenolic Compounds on α-synucleinKenjiro Ono0Mayumi Tsuji1Tritia R. Yamasaki2Giulio M. Pasinetti3Division of Neurology, Department of Internal Medicine, School of Medicine, Showa University, Tokyo 142-8666, JapanPharmacological Research Center, Showa University, Tokyo 142-8666, JapanDepartment of Neurology, University of Kentucky, Lexington, KY 40536, USADepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USAThe aggregation and deposition of α-synuclein (αS) are major pathologic features of Parkinson’s disease, dementia with Lewy bodies, and other α-synucleinopathies. The propagation of αS pathology in the brain plays a key role in the onset and progression of clinical phenotypes. Thus, there is increasing interest in developing strategies that attenuate αS aggregation and propagation. Based on cumulative evidence that αS oligomers are neurotoxic and critical species in the pathogenesis of α-synucleinopathies, we and other groups reported that phenolic compounds inhibit αS aggregation including oligomerization, thereby ameliorating αS oligomer-induced cellular and synaptic toxicities. Heterogeneity in gut microbiota may influence the efficacy of dietary polyphenol metabolism. Our recent studies on the brain-penetrating polyphenolic acids 3-hydroxybenzoic acid (3-HBA), 3,4-dihydroxybenzoic acid (3,4-diHBA), and 3-hydroxyphenylacetic acid (3-HPPA), which are derived from gut microbiota-based metabolism of dietary polyphenols, demonstrated an in vitro ability to inhibit αS oligomerization and mediate aggregated αS-induced neurotoxicity. Additionally, 3-HPPA, 3,4-diHBA, 3-HBA, and 4-hydroxybenzoic acid significantly attenuated intracellular αS seeding aggregation in a cell-based system. This review focuses on recent research developments regarding neuroprotective properties, especially anti-αS aggregation effects, of phenolic compounds and their metabolites by the gut microbiome, including our findings in the pathogenesis of α-synucleinopathies.https://www.mdpi.com/1420-3049/25/10/2444Parkinson’s diseaseα-synucleinphenolic compoundsgut microbiome
spellingShingle Kenjiro Ono
Mayumi Tsuji
Tritia R. Yamasaki
Giulio M. Pasinetti
Anti-aggregation Effects of Phenolic Compounds on α-synuclein
Molecules
Parkinson’s disease
α-synuclein
phenolic compounds
gut microbiome
title Anti-aggregation Effects of Phenolic Compounds on α-synuclein
title_full Anti-aggregation Effects of Phenolic Compounds on α-synuclein
title_fullStr Anti-aggregation Effects of Phenolic Compounds on α-synuclein
title_full_unstemmed Anti-aggregation Effects of Phenolic Compounds on α-synuclein
title_short Anti-aggregation Effects of Phenolic Compounds on α-synuclein
title_sort anti aggregation effects of phenolic compounds on α synuclein
topic Parkinson’s disease
α-synuclein
phenolic compounds
gut microbiome
url https://www.mdpi.com/1420-3049/25/10/2444
work_keys_str_mv AT kenjiroono antiaggregationeffectsofphenoliccompoundsonasynuclein
AT mayumitsuji antiaggregationeffectsofphenoliccompoundsonasynuclein
AT tritiaryamasaki antiaggregationeffectsofphenoliccompoundsonasynuclein
AT giuliompasinetti antiaggregationeffectsofphenoliccompoundsonasynuclein